Sonidegib/Erismodegib..Novartis Cancer Drug LDE225 Meets Primary Endpoint in Phase 2

Sonidegib/Erismodegib..Novartis Cancer Drug LDE225 Meets Primary Endpoint in Phase 2
http://newdrugapprovals.org/2014/02/20/sonidegiberismodegib-novartis-cancer-drug-lde225-meets-primary-endpoint-in-phase-2/

Post a comment

Private comment